Tag: Pfizer

Pfizer Inc. is an American global pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. It is among the world’s largest pharmaceutical companies. Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology.

Pfizer’s Fragmin Granted FDA Approval

The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric pati...

FDA Approved Bavencio for Treatment of Patients with Advanced Renal Cell Carcinoma

cancer-drugs
Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of patients with advanced ren...

Pfizer Selected First Drug Candidate From Pfizer-Sosei Alliance

Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR) class. ...

Pfizer Opened New Manufacturing Facility in USA

Pfizer Inc. announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Mass. Pfizer’s Andover site houses commercial manufacturing and product development functions, with co...

Pfizer Agreed to Acquire Clinical-Stage Biotech Therachon

pfizer
Pfizer today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases...

EС Approved Pfizer’s LORVIQUA®

Pfizer Inc. announced today that the European Commission (EC) granted conditional marketing authorization for LORVIQUA® (lorlatinib, available in the U.S., Canada and Japan under the brand name LORBRE...

Pfizer Received FDA Approval for ATTR-CM Drug

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and VYNDAMAX™ (tafamidis) for the treatment of the cardiomyopathy of wild-type ...

Pfizer Q1 Profit Up 9%

Higher prescription drugs sales and restrained spending together gave drugmaker Pfizer a 9% jump in first quarter profit as it easily topped analysts' profit expectations. Sales of breast cancer drug...

Pfizer, McKesson, AmerisourceBergen Join Contracting Blockchain Group

blockchain
Leading life sciences and healthcare companies Pfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have all joined MediLedger working group that is using blockchain tech...

Nativa Won Several Legal Disputes over Pfizer

The issuing of a compulsory license for the production of a patent-protected drug in Russia may take place shortly, due to the recent victory of several legal disputes with US pharma giant Pfizer by l...

Local Indian Pharma Companies to Challenge MNCs in Pneumonia Vaccine

The duopoly of pneumonia vaccines in India is in for some shake-up soon, as homegrown players like Aurobindo Pharma, Cadila Healthcare (Zydus Cadila), and Serum Institute are readying their vaccin...

Pfizer’s Company Recalled Metabolic Acidosis Drugs

Hospira, Inc., a Pfizer company, announced that it was voluntarily recalling lot numbers 79-238-EV, 79-240-EV and 80-088-EV, NDC# 0409-6625-02, of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (...

Pfizer and Vivet Collaborate to Fight Rare Disease

Vivet Therapeutics, a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. announced ...

Pfizer and Merck Cease Phase III Study for Treatment Ovarian Cancer

Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. announced the discontinuation of the ongoing Phase III JAVELIN Ovarian...

Phase 4 Results of BMS-Pfizer Trial

The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibri...

FDA Approved Lupin’s Generic of Pfizer to Market

Pharma major Lupin announced that it has received approval for its Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, from the United States Food and Drug Administration (FDA) to market...